title: PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
abstract: OBJECTIVE
  The aim of this study is to identify single-nucleotide polymorphisms (SNPs) influencing blood pressure (BP) response to the β-blocker atenolol.
  
  
  METHODS
  Genome-wide association analysis of BP response to atenolol monotherapy was performed in 233 white participants with uncomplicated hypertension in the pharmacogenomic evaluation of antihypertensive responses study. Forty-two polymorphisms with P less than 10 for association with either diastolic or systolic response to atenolol monotherapy were validated in four independent groups of hypertensive individuals (total n = 2114).
  
  
  RESULTS
  In whites, two polymorphisms near the gene PTPRD (rs12346562 and rs1104514) were associated with DBP response to atenolol (P = 3.2 × 10 and P = 5.9 × 10, respectively) with directionally opposite association for response to hydrochlorothiazide in another group of 228 whites (P = 0.0018 and P = 0.00012). A different polymorphism (rs10739150) near PTPRD was associated with response to atenolol in 150 black hypertensive individuals (P = 8.25 × 10). rs12346562 had a similar trend in association with response to bisoprolol (a different β-blocker) in 207 Finnish men in the genetics of drug responsiveness in essential hypertension study. In addition, an intronic single-nucleotide polymorphism (rs4742610) in the PTPRD gene was associated with resistant hypertension in whites and Hispanics in the international verapamil SR trandolapril study (meta-analysis P = 3.2 × 10).
  
  
  CONCLUSIONS
  PTPRD was identified as a novel locus potentially associated with BP response to atenolol and resistant hypertension in multiple ethnic groups.
authors.affiliation: aDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida USA bDepartment of Medicine and Program in Personalized and Genomic Medicine, University of Maryland, Baltimore, Maryland, USA cDepartment of Medicine, University of Helsinki, and University Central Hospital of Helsinki, Helsinki, Finland dBHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK eDepartment of Community Health and Family Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA fInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. gCollege of Medicine, Mayo Clinic Rochester, Rochester, Minnesota USA hCenter for Human Genetics, University of Texas at Houston, Houston, Texas, USA iRIKEN Center for Integrative Medical Sciences, Yokohama, Japan jSchool of Medicine, Emory University, Atlanta, Georgia, USA kDivision of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Gong
authors.forename: Caitrin W
authors.initials: CW
authors.lastname: McDonough
authors.forename: Amber L
authors.initials: AL
authors.lastname: Beitelshees
authors.forename: Nihal
authors.initials: N
authors.lastname: El Rouby
authors.forename: Timo P
authors.initials: TP
authors.lastname: Hiltunen
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: O'Connell
authors.forename: Sandosh
authors.initials: S
authors.lastname: Padmanabhan
authors.forename: Taimour Y
authors.initials: TY
authors.lastname: Langaee
authors.forename: Karen
authors.initials: K
authors.lastname: Hall
authors.forename: Siegfried O F
authors.initials: SO
authors.lastname: Schmidt
authors.forename: Robert W
authors.initials: RW
authors.lastname: Curry
authors.forename: John G
authors.initials: JG
authors.lastname: Gums
authors.forename: Kati M
authors.initials: KM
authors.lastname: Donner
authors.forename: Kimmo K
authors.initials: KK
authors.lastname: Kontula
authors.forename: Kent R
authors.initials: KR
authors.lastname: Bailey
authors.forename: Eric
authors.initials: E
authors.lastname: Boerwinkle
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takahashi
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Tanaka
authors.forename: Michiaki
authors.initials: M
authors.lastname: Kubo
authors.forename: Arlene B
authors.initials: AB
authors.lastname: Chapman
authors.forename: Stephen T
authors.initials: ST
authors.lastname: Turner
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Pepine
authors.forename: Rhonda M
authors.initials: RM
authors.lastname: Cooper-DeHoff
authors.forename: Julie A
authors.initials: JA
authors.lastname: Johnson
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use*; D044383:Black People / Q000235:genetics; D001794:Blood Pressure / Q000187:drug effects* / Q000235:genetics*; D000075222:Essential Hypertension; D005260:Female; D055106:Genome-Wide Association Study; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D054623:Receptor-Like Protein Tyrosine Phosphatases, Class 2 / Q000235:genetics*; D044465:White People / Q000235:genetics
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001262:Atenolol; C090899:PTPRD protein, human; D054623:Receptor-Like Protein Tyrosine Phosphatases, Class 2